Website survey

Help us improve! Please fill out this quick survey to provide feedback on how we can improve the website to better meet your needs…

Read more

Cornell campus panorama

Cornell University study identifies critical genes involved in FLC

In this study published in Cell Reports, FCF-funded researcher Praveen Sethupathy and his team at Cornell University have leveraged a novel genomics technology to uncover therapeutic vulnerabilities in fibrolamellar carcinoma. Collaborators on the study include FCF-funded John Scott and F. Donelson Smith at the University of Washington. The lead author is Tim Dinh, who recently …

Read more

A red letter day for FLC

April 21st was a red letter day for the fibrolamellar community. A patient at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, Baltimore, MD received the initial treatment of the first experimental therapy aimed to directly target the primary molecular cause of fibrolamellar carcinoma (FLC)…

Read more

During this time of COVID-19

The emerging COVID-19 pandemic has created unprecedented global challenges. We know that for individuals with underlying conditions, including cancer, the situation may seem fraught with uncertainty. We urge patients and caregivers to reach out …

Read more

Sidney Kimmel Comprehensive Cancer Center photo

Opening of FLC peptide vaccine clinical trial

A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …

Read more

Mark Foundation Aspire Award granted for fibrolamellar research

The Fibrolamellar Cancer Foundation (FCF) is proud to announce The Mark Foundation for Cancer Research has awarded their coveted Aspire Award to Dr. Paul Thomas, St. Jude Children’s Research Hospital for fibrolamellar carcinoma immunotherapy research. The Aspire Award …

Read more

Fibro community reviews grants for Department of Defense

Big thanks to Jenny Carroll, Jennifer Strickland and all in the FLC community who participated in the 2019 Department of Defense grant reviews. Since liver cancer has been an approved cancer for DOD funding, Fibrolamellar has been awarded over $2 million in support…

Read more

October 1 is Rare Cancer Day

FCF Press Release on Rare Disease Day Tuesday October 1, 2019 is Rare Cancer Day. The event this year is especially important because at the Fibrolamellar Cancer Foundation (FCF) we are celebrating ten years of bringing awareness to this disease. We are proud to have contributed nearly $8 million to researching cures and treatments for …

Read more